Welcome to our dedicated page for Kamada news (Ticker: KMDA), a resource for investors and traders seeking the latest updates and insights on Kamada stock.
Kamada Ltd (KMDA) is a global biopharmaceutical company focused on specialty plasma-derived therapies and other biopharmaceutical products for rare and serious conditions. Its news flow reflects activity across commercial operations, clinical programs, plasma collection, and corporate strategy.
On this page, readers can follow Kamada news related to its proprietary products such as KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and equine-based anti-snake venom products. Company announcements frequently discuss revenue trends, adjusted EBITDA, and guidance, highlighting the contribution of its Proprietary Products and Distribution segments, including biosimilar launches in Israel and supply agreements in markets such as Canada.
News items also cover clinical and post-marketing research, including updates on the InnovAATe Phase 3 trial of Inhaled AAT for Alpha-1 Antitrypsin Deficiency and its subsequent discontinuation following an interim futility analysis, as well as the SHIELD study evaluating CYTOGAM in high-risk kidney transplant recipients. Regulatory and operational milestones, such as FDA approval of the Houston, Texas plasma collection center and expansion of plasma collection capacity across Kamada’s three Texas sites, are recurring topics.
Investors and followers of KMDA stock can use this feed to track quarterly and annual financial results, guidance updates, tender awards like the Canadian Blood Services supply extension, and participation in healthcare and investor conferences. Regularly reviewing this page provides a consolidated view of Kamada’s commercial progress, R&D developments, and strategic initiatives as reported in its press releases and related filings.
Kamada Ltd. (NASDAQ: KMDA) has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020, with the SEC. The report includes audited consolidated financial statements, accessible on the SEC's website and Kamada's investor relations site. Kamada specializes in plasma-derived biopharmaceuticals with a focus on orphan indications. Their leading product, GLASSIA®, is the first liquid AAT product approved by the FDA. Kamada also has a late-stage product pipeline, including inhaled AAT formulations and a new hyperimmune immunoglobulin for COVID-19 treatment.
Kamada Ltd. (NASDAQ: KMDA) reported full-year 2020 revenues of $133.2 million, aligning with guidance and marking a 5% increase from 2019. The company overcame operational challenges from the COVID-19 pandemic, achieving adjusted EBITDA of $25.1 million. Kamada has entered the U.S. plasma collection market through the acquisition of an FDA-approved facility, aiming to expand its hyperimmune IgG portfolio. Additionally, it is supplying a plasma-derived COVID-19 product to the Israeli Ministry of Health, expecting about $3.4 million in related revenue.
Kamada Ltd. (NASDAQ: KMDA), a plasma-derived biopharmaceutical company, will release its financial results for Q4 and fiscal year 2020 on February 10, 2021, before U.S. market open. A conference call will follow at 8:00 AM ET for discussion and Q&A. Kamada is known for its proprietary plasma-derived products, including GLASSIA® and KamRab®, both FDA-approved. The company has late-stage developments, including an inhaled AAT formulation and treatments for COVID-19. FIMI Opportunity Fund is the largest shareholder, owning about 21% of shares.
Kamada Ltd. (Nasdaq: KMDA) has announced its acquisition of Blood and Plasma Research, Inc., located in Beaumont, TX, for approximately $1.63 million. This acquisition marks Kamada's entry into the U.S. plasma collection market and aims to expand its collection capacity of hyper-immune plasma essential for manufacturing the Anti-D immunoglobulin. Kamada plans to enhance its operations by leveraging B&PR’s FDA license to open more centers in the U.S. The deal is projected to close within this quarter, subject to specific conditions.
Kamada Ltd. (NASDAQ: KMDA) has signed an agreement with the Israeli Ministry of Health to supply its investigational anti-SARS-CoV-2 hyperimmune immunoglobulin product for COVID-19 treatment. This initial order will treat around 500 patients and is projected to generate roughly $3.4 million in revenue during Q1 2021. Positive interim results from an ongoing Phase 1/2 trial show favorable safety and symptom improvement in non-ventilated COVID-19 patients. U.S. clinical development is anticipated to commence in early 2021, pending IND acceptance.
Kamada Ltd. (NASDAQ: KMDA) announced it expects to receive approximately $25 million in revenue from the sale of GLASSIA® to Takeda in 2021, which represents Takeda's minimum commitment for that year. The total revenue guidance for Kamada for the full year 2020 remains $132 million to $137 million.
Future royalty payments from Takeda are projected to range from $10 million to $20 million annually from 2022 to 2040. Kamada is preparing to adjust its manufacturing plans in light of these developments and is exploring additional business opportunities to enhance future growth.
Kamada Ltd. (NASDAQ: KMDA) announced changes in its Board of Directors. Lilach Asher Topilsky, currently a Director and Senior Partner at FIMI Opportunity Funds, has been appointed Chairman, succeeding Leon Recanati, who remains a Director. Additionally, Ari Shamiss, a veteran hospital executive, has joined the Board. The leadership transition comes as Kamada boasts two FDA-approved products and a promising clinical pipeline, including an immunoglobulin product for COVID-19 under development. FIMI, the largest shareholder, recently made a significant investment in Kamada.
Kamada Ltd. (NASDAQ: KMDA) reported a 6% decrease in Q2 revenues, generating $33.1 million, compared to $35.3 million in 2019. However, H1 2020 revenues rose 7% to $66.4 million. Net income for Q2 was $3.5 million ($0.08/share), down from $6.1 million in Q2 2019. The company is developing a plasma-derived IgG product for COVID-19, with initial batches completed and a clinical trial underway. Cash position stands strong at $104.7 million. The full-year revenue guidance is maintained at $132 million to $137 million.